CoChat
Sign Up
Cited by 136Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCholesterol and Lipid Metabolism

Low-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart Disease

Open access
Mendivil, Carlos O., Rimm, Eric B., Furtado, Jeremy, Chiuve, Stephanie E., Sacks, Frank M.·2011·Circulation
DOI 10.1161/circulationaha.111.056986PMC PMC3244212
Open this paper in CoChat — free account

Abstract

Background—: Low-density lipoprotein (LDL) that contains apolipoprotein (apo) C-III makes up only 10% to 20% of plasma LDL but has a markedly altered metabolism and proatherogenic effects on vascular cells. Methods and Results—: We examined the association between plasma LDL with apoC-III and coronary heart disease in 320 women and 419 men initially free of cardiovascular disease who developed a fatal or nonfatal myocardial infarction during 10 to 14 years of follow-up and matched controls who remained free of coronary heart disease. Concentrations of LDL with apoC-III (measured as apoB in this fraction) were associated with risk of coronary heart disease in multivariable analysis that included the ratio of total cholesterol to high-density lipoprotein cholesterol, LDL cholesterol, apoB, triglycerides, or high-density lipoprotein cholesterol and other risk factors. In all models, the relative risks for the top versus bottom quintile of LDL with apoC-III were greater than those for LDL without apoC-III. When included in the same multivariable-adjusted model, the risk associated with LDL with apoC-III (relative risk for top versus bottom quintile, 2.38; 95% confidence interval, 1.54–3.68; P for trend <0.001) was significantly greater than that associated with LDL without apoC-III (relative risk for top versus bottom quintile, 1.25; 95% confidence interval, 0.76–2.05; P for trend=0.97; P for interaction <0.001). This divergence in association with coronary heart disease persisted even after adjustment for plasma triglycerides. Conclusions—: The risk of coronary heart disease contributed by LDL appeared to result to a large extent from LDL that contains apoC-III.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.111.056986

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • APOC-III is considered an independent risk factor for cardiovascular disease.

    “Consequently, APOC-III is considered an independent risk factor for cardiovascular disease [30, 31].”

    From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [30]

    The Discussion reports that LDL containing apoC-III is independently associated with coronary heart disease risk, and the Results show that association persisted after adjustment for other lipid risk factors. The paper does not establish apoC-III itself as an independent risk factor for cardiovascular disease broadly; its finding concerns a specific LDL fraction and coronary heart disease. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 24

  1. [1]Alaupovic P Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins Methods Enzymol 1996 263 32 60 8748999
  2. [2]Campos H Perlov D Khoo C Sacks FM Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia J Lipid Res 2001 42 1239 1249 11483625
  3. [3]Lee SJ Campos H Moye LA Sacks FM LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients Arterioscler Thromb Vasc Biol 2003 23 853 858 12637336
  4. [7]Kawakami A Yoshida M Apolipoprotein CIII links dyslipidemia with atherosclerosis J Atheroscler Thromb 2009 16 6 11 19262004
  5. [8]Sehayek E Eisenberg S Mechanisms of inhibition by apolipoprotein C of apolipoprotein E dependent cellular metabolism of human triglyceride rich lipoproteins through the low density lipoprotein receptor pathway J Biol Chem 1991 266 18259 18267 1917954
  6. [9]Zheng C Khoo C Furtado J Sacks FM Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype Circulation 2010 121 1722 1734 20368524 PMC3153990
  7. [10]Kawakami A Aikawa M Alcaide P Luscinskas FW Libby P Sacks FM Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells Circulation 2006 114 681 687 16894036
  8. [11]Kawakami A Aikawa M Libby P Alcaide P Luscinskas FW Sacks FM Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells Circulation 2006 113 691 700 16461842
  9. [12]Kawakami A Osaka M Tani M Azuma H Sacks FM Shimokado K Yoshida M Apolipoprotein CIII links hyperlipidemia with vascular endothelial function Circulation 2008 118 731 742 18663085
  10. [13]Hiukka A Ståhlman M Pettersson C Levin M Adiels M Teneberg S Leinonen ES Hultén LM Wiklund O Oresic M Olofsson SO Taskinen MR Ekroos K Borén J ApoCIII-Enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan Diabetes 2009 58 2018 2026 19502413 PMC2731525
  11. [15]Hodis HN Mack WJ Azen SP Alaupovic P Pogoda JM LaBree L Hemphill LC Kramsch DM Blankenhorn DH Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin Circulation 1994 90 42 49 8026027
  12. [16]Luc G Fievet C Arveiler D Evans AE Bard JM Cambien F Fruchart JC Ducimetiere P Apolipoproteins C-III and E in apoB- and non-apoB containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur ‘Infarctus du Myocarde J Lipid Res 1996 37 508 517 8728314
  13. [18]Rimm EB Giovannucci EL Stampfer MJ Colditz GA Litin LB Willett WC Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals Am J Epidemiol 1992 135 1114 1126 1632423
  14. [19]Colditz GA Manson JE Hankinson SE The Nurses’ Health Study: 20-year contribution to the understanding of health among women J Womens Health 1997 6 49 62 9065374
  15. [23]Khoo C Judge H Sacks FM Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content J Lipid Res 1999 40 202 212 9925648
  16. [24]Pietzsch J Subat S Nitzsche S Leonhardt W Schentke KU Hanefeld M Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition Biochim Biophys Acta 1995 1254 77 88 7811751
  17. [26]Kawakami A Osaka M Aikawa M Uematsu S Akira S Libby P Shimokado K Sacks FM Yoshida M Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation Circ Res 2008 103 1402 1409 18974386 PMC2994199
  18. [27]Kawakami A Aikawa M Nitta N Yoshida M Libby P Sacks FM Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation Arterioscler Thromb Vasc Biol 2007 27 219 225 17038637
  19. [29]Alaupovic P Mack WJ Knight-Gibson C Hodis HN The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial Arterioscler Thromb Vasc Biol 1997 17 715 722 9108785
  20. [30]Lee SJ Sacks FM Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus Am J Cardiol 2003 92 121 124 12860210
  21. [31]Cohn JS Rodriguez C Jacques H Tremblay M Davignon J Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE J Lipid Res 2004 45 1572 1579 15145987
  22. [32]Wilson PW D’Agostino RB Levy D Belanger AM Silbershatz H Kannel WB Prediction of coronary heart disease using risk factor categories Circulation 1998 97 1837 1847 9603539
  23. [33]Assmann G Cullen P Schulte H Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study Circulation 2002 105 310 315 11804985
  24. [34]Ridker PM Buring JE Rifai N Cook NR Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score JAMA 2007 297 611 619 17299196

Cited by

Sorted by citations

Authors
Mendivil, C. O., Rimm, E. B., Furtado, J., Chiuve, S. E., & Sacks, F. M.
Affiliations
Brigham and Women's Hospital (US)
ORCID
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2011-11-08
Volume
124
Issue
19
Pages
2065-2072
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
DOI
10.1161/circulationaha.111.056986
PMC
PMC3244212
OpenAlex
W2134450273
Cited by
136
References
8
Citations by year
2026: 2 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 7 · 2020: 8 · 2019: 6 · 2018: 14 · 2017: 14 · 2016: 12 · 2015: 14 · 2014: 11 · 2013: 12 · 2012: 11
FWCI
11.14
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • National Heart, Lung, and Blood Institute (HL070159, R01HL070159)
  • National Center for Research Resources (UL1RR025758)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
apolipoprotein C-III, low-density lipoprotein, coronary artery disease, myocardial infarction, apolipoprotein B, triglyceride-rich lipoproteins, atherogenic lipoproteins, cardiovascular risk factors, triglycerides
MeSH terms
Adult, Aged, Apolipoproteins B, Coronary Disease, Female, Follow-Up Studies, Humans, Lipoproteins, LDL, Lipoproteins, VLDL, Male, Middle Aged, Prospective Studies, Risk Factors, Triglycerides, Hypertriglyceridemia, Estrogen Replacement Therapy, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review